Tenofovir amibufenamide:A potential alternative for chronic hepatitis B treatment  

作　　者：Hai-Nan Ma Kai-Sen Cao Yan-Miao Liu Cheng Chen Hang Zhang Fu-Shan Tang 

机构地区：[1]Department of Clinical Pharmacy,Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy,Zunyi Medical University,Zunyi 563006,Guizhou Province,China [2]Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education,Zunyi Medical University,Zunyi 563006,Guizhou Province,China [3]Key Laboratory of Clinical Pharmacy in Zunyi City,Zunyi Medical University,Zunyi 563006,Guizhou Province,China

出　　处：《World Journal of Gastroenterology》2025年第10期139-143,共5页世界胃肠病学杂志(英文)

摘　　要：Tenofovir amibufenamide(TMF)is a novel prodrug of tenofovir that demonstrates a promising safety and efficacy profile.A recent study by Peng et al compared TMF with tenofovir alafenamide in the treatment of chronic hepatitis B.The findings indicated that both medications offer similar efficacy in terms of viral response and alanine aminotransferase normalization.Notably,TMF showed potential advantages in lipid management,as it did not significantly affect cholesterol levels,unlike tenofovir alafenamide.This correspondence highlights the need for further research to evaluate the long-term safety and efficacy of TMF,its impact on cardiovascular risk,and its use in specific patient populations.

关 键 词：Tenofovir amibufenamide Tenofovir alafenamide Chronic hepatitis B Antiviral efficacy Safety profile HYPERLIPIDEMIA 

分 类 号：R57[医药卫生—消化系统]